What Ruixing Pharmaceutical does

Guangdong Ruixing Pharmaceutical Co., Ltd. (广东瑞兴医药股份有限公司) is an innovative pharmaceutical enterprise listed on China's New Third Board (NEEQ) under stock code 835553, headquartered in Shunde District, Foshan, Guangdong Province. The company integrates new drug R&D, pharmaceutical production, and nationwide distribution of specialty pharmaceutical products and medical devices, with a therapeutic focus on gynecology, pediatrics, and planned expansion into ophthalmology. Its core product portfolio includes 舒伊 (Shuyi, Nifuratel Nystatin Vaginal Ointment), 尔可芬 (Erkefen, pediatric mefenamin ammonium syrup), 克痒舒洗液 (Keyangshu Lotion — 2017 Gold Brick Award winner), 血尿安片 (Xuening'an Tablets for chronic kidney disease), and danazole soft capsules, alongside orthopedic and respiratory products. Manufacturing is conducted through its core subsidiary Hefei Huawei Pharmaceutical (founded 1995, a national high-tech enterprise with a postdoctoral research workstation and provincial gynecological pharmaceutical engineering center), with additional subsidiaries Meixin Pharmaceutical and Kangzhengde Pharmaceutical.

The company generates revenue through B2B quotation-based sales to hospitals, clinics, pharmacies, and pharmaceutical distributors across China via a direct sales force, a controlled sales (控销) network targeting second- and third-tier terminals, and emerging e-commerce and internet drug information channels. Its go-to-market motion is sales-led and academic-promotion driven, with extensive participation in the National Pharmaceutical Trade Fair and over 50 academic conferences and 20+ distributor training sessions per half-year, alongside partnerships with research institutions in Beijing, Shanghai, Nanjing, and Hefei. Operations span roughly 101-250 employees, a 50,000+ sqm headquarters (Ruixing Chuangxiang Center), a 100-acre approved production base in Hefei, and an industry-academia-research training base partnership with Guangdong Food and Drug Vocational College.

Name

Ruixing Pharmaceutical

Legal name

广东瑞兴医药股份有限公司

Website

https://gdrxyy.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Guangdong Ruixing Pharmaceutical is a NEEQ-listed (835553) Chinese pharmaceutical company integrating new drug R&D, production, and nationwide distribution of specialty drugs and medical devices, focused on gynecology, pediatrics, and related therapeutic areas for hospitals, clinics, and pharmacies across China.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Pharmaceutical manufacturing
• Gynecological medications
• Pediatric pharmaceuticals
• Drug distribution
• Medical device distribution

Headquarters

HQ city

Shunde

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Infrastructure

Revenue model

1. Pharmaceutical R&D, Production and Distribution: The company operates as an innovative pharmaceutical enterprise integrating new drug R&D, production, and sales of pharmaceutical products and medical devices. Revenue is generated through the sale of proprietary and distributed pharmaceutical products across China's national market.
2. Medical Device Sales: The company distributes medical devices alongside pharmaceutical products, expanding its revenue streams through the sale of medical supplies.
3. E-commerce and Digital Health Platforms: Ruixing actively develops pharmaceutical e-commerce and internet innovation platforms as part of its strategic expansion into digital health business.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Guangdong Ruixing Pharmaceutical Co., Ltd. is an innovative pharmaceutical enterprise that integrates new drug R&D, pharmaceutical production, and distribution of pharmaceutical products and medical devices. The company's product portfolio is concentrated in gynecology and pediatric therapeutic areas, with partnerships with research institutions in Beijing, Shanghai, Nanjing, and Hefei for new drug development. It operates a national marketing and sales network across China, distributing both proprietary and third-party manufactured specialty pharmaceuticals.

Product overview

Ruixing Pharmaceutical is a pharmaceutical company operating as a New Third Board listed entity (stock code: 835553). The company focuses on new drug R&D, pharmaceutical manufacturing, and distribution of domestic and international specialty pharmaceuticals. Its product portfolio centers on specialized therapeutic areas — primarily women's health (gynecology) and pediatrics — along with broader pharmaceutical offerings. Key products include 舒伊 (Nifuratel Nystatin Vaginal Ointment), 尔可芬 (Mepronyl Ammonium Syrup), 克痒舒洗液 (Keyangshu Gynecological Lotion), 血尿安片 (Xuening'an Tablets for kidney disease), 达那唑软胶囊 (Danazole Soft Capsules), along with musculoskeletal products such as 风湿骨痛片 and 橘红枇杷胶囊. The company also operates a pharmaceutical e-commerce business unit and provides internet drug information services. The product structure follows a core-brand-plus-portfolio model, anchored by gynecological and pediatric specialties with expansion into broader therapeutic categories.

Differentiator

Problem solved

Functional benefit

Products and services

• Shuyi (舒伊) — Nifuratel Nystatin Vaginal Soft Ointment

Quantifiable outcome

• 克痒舒洗液 won the 2017 Gold Brick Award for Most Market Potential Gynecological Medication, demonstrating strong product market reception.
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered minor, flagship and core.

• Guangdong Food and Drug Vocational College (广东食品药品职业学院)minorStrategic or Co-development Partner · 10 November 2017Ruixing Pharmaceutical signed a strategic cooperation framework agreement with Guangdong Food and Drug Vocational College on November 10, 2017, establishing a talent training and industry-academia-research collaboration platform. The partnership includes order-based classes (订单班), industry knowledge enhancement training, off-campus practical training, research cooperation, and innovation achievement transformation. Ruixing was granted '产学研实训基地' (Industry-Academia-Research Practical Training Base) status, and the company's General Manager Luan Guanggen and Vice General Manager Zhou Yi were appointed as visiting professors at the college.
• Foshan Municipal Government (佛山市委/市政府)flagshipOthersThe Ruixing Chuangxiang Center project was visited and investigated by Foshan Party Secretary Lu Yi and Mayor Zhu Wei as part of the Sanlong Bay high-end innovation cluster development initiative. The project was designated as a provincial key construction project and Shunde key investment attraction project, receiving government recognition and support for its role in regional biotech industry development.
• Hefei Huawei Pharmaceutical (合肥华威药业有限公司)coreStrategic or Co-development PartnerHefei Huawei Pharmaceutical is a subsidiary and core manufacturing entity of the Ruixing group, specializing in gynecological pharmaceutical production. Founded in 1995, Huawei operates a national high-tech enterprise with pharmaceutical R&D, production, and sales capabilities. The company has established a postdoctoral research workstation, enterprise technology center, and Anhui Provincial Gynecological Pharmaceutical Engineering Technology Research Center. Huawei's production facility expansion includes a 6,000+ square meter R&D building with 5 above-ground and 1 underground floor, representing a 20 million RMB investment.
• Shangyao Holdings Foshan Co., Ltd. (上药控股佛山有限公司)coreChannel Partner/ Reseller/ DistributorShangyao Holdings Foshan is co-located in the Ruixing Chuangxiang Center innovation hub as a downstream industry tenant. The company was also a co-recipient of charitable donations from Ruixing during COVID-19, and a Ruixing employee (Deng Yanfang) who fell ill worked at Shangyao, triggering a joint employee fundraising campaign.
• Hilton Hampton Hotel (希尔顿欢朋酒店)minorOthersThe Hilton Hampton Hotel is integrated as a component of the Ruixing Chuangxiang Center commercial complex, providing hospitality services within the company's headquarters innovation hub. The hotel occupies a portion of the multi-functional creative commercial space within the 50,000+ square meter complex.
• Nanjing University Pharmaceutical (南京南大药业)coreChannel Partner/ Reseller/ DistributorNanjing University Pharmaceutical is the manufacturer of 舒伊 (Shuyi) Nifuratel Nystatin Vaginal Soft Ointment, one of Ruixing's key distributed products. The company participated in Ruixing's strategic partner conference alongside other key product partners including Nanjing Housheng Pharmaceutical (product certificate holder for Shuyi).

Scale indicators6 records

Recent moves11 records

Expansion highlights5 records

Emerging players

• Yiling Pharmaceutical: Yiling is a Chinese specialty pharma combining TCM and evidence-based products targeting hospital and OTC channels with proprietary clinical evidence, comparable to Ruixing's emphasis on academic promotion and clinical pathway inclusion.
• Yangshengtang Pharmaceutical: Yangshengtang is a smaller Chinese specialty pharma combining herbal and chemical preparations with proprietary brand focus, broadly comparable in scale and channel mix to Ruixing's NEEQ-listed profile.

Broad incumbents

• Yunnan Baiyao Group: Yunnan Baiyao is a much larger, established Chinese pharmaceutical with branded specialty products and vertical integration from TCM raw materials through distribution, serving as an aspirational comparable for branded specialty pharma in China.
• Shanghai Pharmaceuticals Holding: Shanghai Pharmaceuticals is a major Chinese pharma + distribution incumbent serving nationwide hospital and pharmacy channels. Its distribution scale and integration profile mirror the channel-side of Ruixing's model at far greater size.
• Jiangsu Hengrui Pharmaceuticals: Hengrui is a dominant Chinese innovator pharma with deep specialty pipelines and academic promotion infrastructure. It illustrates the large-scale archetype that successful specialty players like Ruixing aim to scale toward.

Direct peers

• Livzon Pharmaceutical Group: Livzon is a Chinese specialty pharma with a long-standing gynecology franchise (e.g., Lizhu Chufeng) and integrated R&D-manufacturing-distribution model, making it the most direct comparable for Ruixing's women's-health focus and channel strategy.
• China Resources Sanjiu Medical & Pharmaceutical: CR Sanjiu is a China Resources Group specialty pharma with branded OTC and specialty product portfolio, integrated manufacturing-distribution, and a similar mix of proprietary and distributed brands serving Tier 2/3 Chinese hospitals and pharmacies.
• Kelun Pharmaceutical: Kelun is a Chinese integrated pharma with manufacturing, infusion, and branded specialty distribution, sharing Ruixing's profile of combining manufacturing capacity with hospital-channel sales and academic promotion.
• Shandong Buchang Pharmaceuticals: Buchang is a Chinese specialty pharma combining TCM and chemical drugs, with strong academic promotion and a hospital-channel footprint overlapping Ruixing's controlled-sales (控销) model targeting provincial OB/GYN and internal medicine physicians.

Regional players

• Sinopharm Group: Sinopharm is China's largest pharmaceutical distributor with national warehousing and hospital supply networks, providing a benchmark for the channel scale that Ruixing aims to build out across all Chinese provinces.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ruixing Pharmaceutical